Vanguard Group Inc. Reduces Stock Position in Merit Medical Systems, Inc. $MMSI

Vanguard Group Inc. lessened its holdings in shares of Merit Medical Systems, Inc. (NASDAQ:MMSI) by 2.7% during the third quarter, Holdings Channel reports. The firm owned 6,643,438 shares of the medical instruments supplier’s stock after selling 185,798 shares during the quarter. Vanguard Group Inc. owned approximately 0.11% of Merit Medical Systems worth $552,933,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Norges Bank purchased a new stake in Merit Medical Systems in the second quarter worth $53,697,000. Thrivent Financial for Lutherans boosted its stake in shares of Merit Medical Systems by 250.5% during the 3rd quarter. Thrivent Financial for Lutherans now owns 750,066 shares of the medical instruments supplier’s stock valued at $62,428,000 after purchasing an additional 536,072 shares in the last quarter. Bessemer Group Inc. boosted its position in Merit Medical Systems by 160,206.3% during the 3rd quarter. Bessemer Group Inc. now owns 203,589 shares of the medical instruments supplier’s stock valued at $16,946,000 after acquiring an additional 203,462 shares in the last quarter. Franklin Resources Inc. grew its holdings in shares of Merit Medical Systems by 25.9% during the 2nd quarter. Franklin Resources Inc. now owns 884,607 shares of the medical instruments supplier’s stock worth $82,693,000 after acquiring an additional 181,815 shares during the period. Finally, Greenhouse Funds LLLP raised its position in shares of Merit Medical Systems by 44.2% in the 2nd quarter. Greenhouse Funds LLLP now owns 587,912 shares of the medical instruments supplier’s stock worth $54,958,000 after acquiring an additional 180,125 shares in the last quarter. 99.66% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

MMSI has been the topic of several research reports. Needham & Company LLC restated a “buy” rating and set a $108.00 price target on shares of Merit Medical Systems in a research report on Friday, January 9th. Weiss Ratings reissued a “hold (c)” rating on shares of Merit Medical Systems in a research note on Monday, December 29th. BTIG Research started coverage on shares of Merit Medical Systems in a report on Friday, February 6th. They issued a “buy” rating and a $107.00 price objective on the stock. Barrington Research reiterated an “outperform” rating and set a $106.00 target price on shares of Merit Medical Systems in a report on Friday, November 14th. Finally, Piper Sandler reduced their price objective on Merit Medical Systems from $113.00 to $106.00 and set an “overweight” rating for the company in a research report on Wednesday, February 18th. Nine equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $105.67.

Trending Headlines about Merit Medical Systems

Here are the key news stories impacting Merit Medical Systems this week:

• Positive Sentiment: Q4 results beat — EPS of $1.04 vs. consensus $0.96 and revenue of $393.9M vs. $390.8M; revenue grew ~10.9% year-over-year, with reported net margin ~8% and ROE ~14%. These metrics point to demand recovery and margin improvement. Merit Medical Systems Earnings Report
• Positive Sentiment: Upside FY2026 guidance — management raised full‑year EPS to $4.010–4.150 versus the prior consensus (~$3.73), implying stronger margin expansion and earnings growth for 2026. This is the main catalyst supporting the stock’s move higher. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Analyst/press coverage detailing quarter and metrics — third‑party writeups (Zacks) confirm the beat and walk through key metric comparisons to estimates and prior year results; useful for due diligence but largely reiterative of company numbers. Merit Medical (MMSI) Q4 Earnings and Revenues Top Estimates
• Neutral Sentiment: Local/summary coverage — CT Post and other outlets published earnings snapshots summarizing the results and call; useful for quick read but unlikely to move the stock beyond the company-provided figures. Merit Medical: Q4 Earnings Snapshot
• Negative Sentiment: Price target trimmed — Needham’s Michael Matson kept a Buy rating but lowered the price target to $101, which signals more conservative near-term upside expectations despite the favorable results. That trimmed PT could cap immediate analyst-driven upside. Merit Medical Systems: Strong Q4 Beat, Upbeat 2026 Outlook…

Merit Medical Systems Stock Up 1.0%

Merit Medical Systems stock opened at $82.43 on Wednesday. The firm has a market cap of $4.89 billion, a price-to-earnings ratio of 42.27, a PEG ratio of 2.22 and a beta of 0.61. The company has a current ratio of 4.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.48. Merit Medical Systems, Inc. has a 12 month low of $77.62 and a 12 month high of $107.27. The stock has a fifty day simple moving average of $84.08 and a two-hundred day simple moving average of $84.98.

Merit Medical Systems Profile

Merit Medical Systems, Inc is a global manufacturer and marketer of a broad range of medical devices used in diagnostic and interventional procedures. The company’s product portfolio encompasses vascular access, drainage, embolotherapy, and interventional oncology devices, as well as radiofrequency ablation systems and hemostasis solutions. These products serve physicians and hospitals in critical care settings and support minimally invasive treatment options across multiple specialties, including cardiology, radiology, oncology, neurology and endoscopy.

Founded in 1987 by Fred Lampropoulos, Merit Medical Systems has grown through both organic development and targeted acquisitions to expand its technology offerings and geographic reach.